Business Context and Reporting Period
Company: Aptevo Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 16, 2022
Event: Entry into a Material Definitive Agreement (Equity Line of Credit).
Key Financial Metrics and Transaction Terms
This filing details a new financing facility rather than historical financial performance. Key terms include:
- Total Commitment: Up to $35,000,000 in common stock sales over a 36-month term.
- Investor: Lincoln Park Capital Fund, LLC.
- Commitment Fee: 99,276 shares of Common Stock issued for no consideration.
- Expense Reimbursement: $15,000 paid to the investor.
- Share Cap (Exchange Cap): Maximum of 981,102 shares (approx. 19.99% of outstanding shares) unless shareholder approval is obtained or the average sale price exceeds $6.14.
- Beneficial Ownership Limit: Investor limited to 4.99% (increasable to 9.99% with consent).
- Minimum Price Threshold: Regular purchases require a closing sale price of at least $1.00.
Material Changes and Transaction Mechanics
The filing establishes a new mechanism for capital raising with the following structure:
- Regular Purchases: Company may require the investor to buy up to 100,000 shares per notice (increasing to 150,000 shares if stock price exceeds $20.00). The purchase price is the lesser of the lowest sale price on the purchase date or the average of the three lowest closing prices in the preceding ten business days.
- Accelerated Purchases: Following a Regular Purchase, the Company may direct an additional purchase of up to 300% of the Regular Purchase amount or 30% of the trading volume, at 96% of the closing price or volume-weighted average price.
- Termination: The Company may terminate the agreement at any time without cost or penalty with one business day's notice.
- Use of Proceeds: Expected to fund clinical and pre-clinical programs and general corporate purposes.
Guidance, Risks, and Contingencies
Management Commentary: The Company retains sole discretion to initiate sales based on market conditions and capital needs. There are no financial or business covenants, restrictions on future financings (with specific exceptions for similar equity lines), or rights of first refusal.
Risks and Contingencies:
- Dilution: Issuance of shares up to the Exchange Cap will dilute existing shareholders.
- Market Conditions: Sales are contingent on the stock price remaining above $1.00 for Regular Purchases.
- Regulatory Conditions: The agreement requires Nasdaq listing approval and the delivery of a prospectus supplement before sales can commence.
- Short Selling: The investor has covenanted not to engage in short selling or hedging of the Common Stock.
Investor Verification Checklist
- Verify the current number of outstanding shares to calculate the exact dilution impact of the 981,102 share cap.
- Confirm the status of the Nasdaq Listing of Additional Shares notification and prospectus supplement filing to determine the Commencement Date.
- Review the Company's cash runway and immediate capital needs to assess the likelihood of utilizing the $35 million facility.
- Monitor the stock price relative to the $1.00 minimum threshold and the $6.14 average price threshold required to bypass the Exchange Cap.
- Check for any subsequent filings regarding the actual issuance of shares under this agreement.